Resveratrol Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go

Report scope. This 2026 Drug Asset Due Diligence Report evaluates Resveratrol as a potential licensing, partnership, acquisition, or option asset. The review separates verified evidence from open diligence questions across clinical development, intellectual property, market positioning, and transaction precedent.

Executive recommendation: CONDITIONAL GO

Resveratrol is a Small molecule drug associated with NLRP3 x SIRT1 x SIRT5 x STAT1 and a global highest development stage of Phase 2. The lead disclosed indication is Parkinson Disease. The current evidence supports a CONDITIONAL GO posture, subject to confirmation of study-level data, ownership, patent coverage, manufacturing readiness, and regional rights.

Decision memo

• Asset: Resveratrol
• Target: NLRP3 x SIRT1 x SIRT5 x STAT1
• Lead indication: Parkinson Disease
• Highest phase: Phase 2
• Matched trials: 61
• Matched result records: 39
• Matched asset deals: 0

Use PatSnap Life Sciences MCP servers to validate the Resveratrol diligence evidence.

1. Asset identity and development status

The first diligence task is entity resolution. Teams should reconcile development codes, nonproprietary names, salts, formulations, combinations, sponsors, and predecessor owners before relying on portfolio counts. For Resveratrol, the MCP profile identifies NLRP3 x SIRT1 x SIRT5 x STAT1 as the primary target context and Parkinson Disease as the lead indication. Global phase labels are useful orientation points, but investment decisions require country- and indication-level status verification.

Confirm the exact molecule, formulation, route, dose, biomarker definition, and current sponsor. Review discontinuations separately from active development so that an historical high phase is not mistaken for a live program.

Use PatSnap Life Sciences MCP servers to validate the Resveratrol diligence evidence.

2. Clinical program: design and endpoint audit

The clinical program should be audited for randomization, comparator relevance, dose selection, endpoint hierarchy, multiplicity, analysis population, geographic mix, and readout timing. Early-stage programs require attention to pharmacokinetics, pharmacodynamics, adverse events, dose-limiting toxicities, and the rationale for the expansion dose.

Use PatSnap Life Sciences MCP servers to validate the Resveratrol diligence evidence.

3. Clinical readouts: what is known

ADJUNCT RESVERATROL OR OMEPRAZOLE IN NON-TRANSFUSION DEPENDENT THALASSEMIA PATIENTS WITH SECONDARY HEMOCHROMATOSIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Study: ISRCTN73258526 (EHA2026). Phase: Not Applicable. Enrollment: 30. Published: 2026-05-12.

AE = occurred in three patients receiving resveratrol (grade 1 bloating, grade 1 fatigue and grade 2 dysgeusia) and one patient receiving placebo (grade 1 bloating). All events were mild and resolved completely after treatment discontinuation. | AE = occurred in three patients receiving resveratrol (grade 1 bloating, grade 1 fatigue and grade 2 dysgeusia) and one patient receiving placebo (grade 1 bloating). All events were mild and resolved completely after treatment discontinuation.

Results from a Two-Year, Phase II Clinical Trial of Resveratrol, Quercetin, and Curcumin (RQC) as a Treatment for Age-Related Macular Degeneration

Study: NCT05062486 (ARVO2025). Phase: Phase 2. Enrollment: 30. Published: 2025-05-04.

Drusen volume = -0.012 mm^3 | Drusen volume = 0.014 mm^3

The Economic Impact of AMD Prevention in AMD Patients with Extra-Large Drusen

Study: NCT05062486 (ARVO2025). Phase: Phase 2. Enrollment: 16. Published: 2025-05-04.

Cost savings = prevention of 68% of new advanced AMD cases could yield up to $1.4-$3.9 billion in annual cost savings.

Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease: The NICE Trial

Study: NCT03743636 (NICE, CTgov). Phase: Phase 3. Enrollment: 90. Published: 2025-01-14.

Six-minute Walk Distance (NR Alone vs. Placebo)(LS Mean) = -6.93 m | Six-minute Walk Distance (NR Alone vs. Placebo)(LS Mean) = 7.00 m

Effect of Resveratrol on Endothelial Function in Patients with CKD and Diabetes

Study: NCT03597568 (Resveratrol and Vascular Function in CKD, Pubmed | Clin J Am Soc Nephrol). Phase: Not Applicable. Enrollment: Not disclosed. Published: 2024-02-01.

Flow-mediated dilation: ratio of geometric mean changes = 1.43(95% CI, 1.15 - 1.77), P-Value = 0.001 | Flow-mediated dilation: ratio of geometric mean changes = 1.43(95% CI, 1.15 - 1.77), P-Value = 0.001

Phase IIa Study of Resveratrol to Enhance Mitochondrial and Physical Function in Older Adults

Study: NCT02123121 (REVIVE, CTgov). Phase: Phase 2. Enrollment: 60. Published: 2023-07-27.

Change From Baseline in Mitochondrial Respiration in Muscle(Mean) = -3.05 nmol O2/s/mg wwt (95%CI, -9.90 to 3.81) | Change From Baseline in Mitochondrial Respiration in Muscle(Mean) = -4.82 nmol O2/s/mg wwt (95%CI, -11.03 to 1.38)

One-Year Results of a Phase 2 Clinical Trial Evaluating Resveratrol, Quercetin, and Curcumin (RQC) for the Treatment of Geographic Atrophy

Study: ARVO2023. Phase: Phase 2. Enrollment: 12. Published: 2023-06-01.

Growth velocity = 0.35 mm^2/year (95%CI, 0.35)

Randomized Double-Blind Placebo-Controlled Proof-of-Concept Trial of Resveratrol, a Plant Polyphenol, for the Outpatient Treatment of Mild Coronavirus Disease (COVID-19)

Study: NCT04400890 (CTgov). Phase: Phase 2. Enrollment: 105. Published: 2023-02-24.

Hospitalization Rates for COVID-19 = 1 Pts | Hospitalization Rates for COVID-19 = 3 Pts

Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

Study: NCT03866200 (CTgov). Phase: Phase 2. Enrollment: 6. Published: 2022-12-09.

Baseline(Mean) = 3.60 Point | Baseline(Mean) = 3.60 Point

Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial.

Study: NCT04867252 (Pubmed | Endocrine). Phase: Phase 2. Enrollment: 88. Published: 2022-09-28.

Menstrual regularity = 18.2 % | Menstrual regularity = 81.4 %

A Phase 1 Study to Assess the Pharmacokinetics and Safety of Ascending Doses of JOTROL Oral Gelcaps in Healthy Subjects, and to Determine the Influence of Food

Study: NCT04668274 (CTgov). Phase: Phase 1. Enrollment: 24. Published: 2022-08-12.

Number of Participants With Treatment-emergent Adverse Events (TEAEs) = 7 Pts | Number of Participants With Treatment-emergent Adverse Events (TEAEs) = 4 Pts

Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19).

Study: NCT04400890 (Pubmed). Phase: Phase 2. Enrollment: 105. Published: 2022-06-29.

Hospitalization = 2 % | Hospitalization = 6 %

Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

Study: NCT01354977 (CTgov). Phase: Phase 2. Enrollment: 20. Published: 2022-03-08.

RD at baseline(Mean) = 6.573 mg/kg/min

Resveratrol and Exercise to Treat Functional Limitations in Late Life

Study: NCT02523274 (CTgov). Phase: Phase 2. Enrollment: 60. Published: 2022-01-13.

Walking Speed(Mean) = -0.04 m/s (95%CI, -0.1 to 0.03) | Walking Speed(Mean) = -0.03 m/s (95%CI, -0.09 to 0.04)

Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL ^TM).

Study: NCT04668274 (Pubmed). Phase: Phase 1. Enrollment: 24. Published: 2022-01-01.

Cmax = 455 ng/mL

Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19)

Study: NCT04400890 (Pubmed). Phase: Phase 2. Enrollment: 105. Published: 2021-09-13.

Hospitalizations = 2 % | Hospitalizations = 6 %

Use of Resveratrol to Decrease Secondary Brain Injury Following Sports-Related Concussions: a Double-Blind, Placebo-Controlled Study

Study: NCT01321151 (REPAIR, CTgov). Phase: Phase 1/2. Enrollment: 12. Published: 2021-02-11.

Liver Function Testing (Aspartate Transaminase [AST]/Alanine Transaminase [ALT] Ratios) to Screen for Adverse Events.(Mean) = 1.57 AST/ALT ratio | Liver Function Testing (Aspartate Transaminase [AST]/Alanine Transaminase [ALT] Ratios) to Screen for Adverse Events.(Mean) = 1.24 AST/ALT ratio

Efficacy and Safety of Resveratrol in the Treatment of Depression: Double-blind Randomized Placebo-controlled Parallel-group Study.

Study: NCT03384329 (CTgov). Phase: Phase 4. Enrollment: 30. Published: 2020-11-17.

Change in Total HDRS-17 Score From Baseline to Week 4(Mean) = -7.2 Point | Change in Total HDRS-17 Score From Baseline to Week 4(Mean) = -9.9 Point

The Effect of Resveratrol in Older Adults With Impaired Glucose Tolerance: a Double-Blind Crossover Study

Study: NCT01375959 (RSV, CTgov). Phase: Not Applicable. Enrollment: 38. Published: 2020-08-26.

Post Meal Glucose Area Under the Curve(Mean) = 508 mg*hr/dL | Post Meal Glucose Area Under the Curve(Mean) = 513 mg*hr/dL

No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial.

Study: NCT02565979 (Pubmed | Am J Clin Nutr). Phase: Not Applicable. Enrollment: 42. Published: 2020-06-03.

Glycated hemoglobin (HbA1c) = 35.8 mmol/mol | Glycated hemoglobin (HbA1c) = 37.6 mmol/mol

The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women

Study: NCT02256540 (CTgov). Phase: Not Applicable. Enrollment: 25. Published: 2020-03-20.

Baseline(Mean) = 4.11 % | Baseline(Mean) = 6.93 %

A Phase II, Open-Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma

Study: NCT00920556 (CTgov). Phase: Phase 2. Enrollment: 24. Published: 2019-02-27.

Any AE = 24 Pts | Any AE = 9 Pts

Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial

Study: NCT02704494 (ReDNeph, Pubmed | Diabetes Metab). Phase: Phase 1. Enrollment: 60. Published: 2019-01-01.

UACR = -46.4 mg/g (95%CI, -64.5 to -28.3) | UACR = 29.9 mg/g (95%CI, 4.9 - 54.9)

RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)

Study: NCT02246660 (RESTORE, CTgov). Phase: Not Applicable. Enrollment: 66. Published: 2018-04-30.

6-Minute Walk Distance, Meters(Mean) = -12.8 m | 6-Minute Walk Distance, Meters(Mean) = 4.6 m

Effect of Resveratrol on Walking Performance in Older People With Peripheral Artery Disease

Study: NCT02246660 (RESTORE, Pubmed | JAMA Cardiol). Phase: Not Applicable. Enrollment: 66. Published: 2017-08-01.

6MWD = 4.6 m | 6MWD = -12.8 m

Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial

Study: NCT02244879 (Pubmed | Acta Diabetol). Phase: Phase 3. Enrollment: 192. Published: 2017-05-01.

PTX3 = 26.3 % | PTX3 = 4.7 %

The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial

Study: NCT02475564 (ResvEndo, CTgov). Phase: Phase 4. Enrollment: 44. Published: 2016-08-05.

Pain Scores Measured by VAS (Visual Analog Scale) at Day 42.(Median) = 3.2 Unit (Full Range, 0 - 8) | Pain Scores Measured by VAS (Visual Analog Scale) at Day 42.(Median) = 3.9 Unit (Full Range, 0 - 8.9)

Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease

Study: NCT01504854 (CTgov). Phase: Phase 2. Enrollment: 119. Published: 2016-06-14.

Number of Adverse Events = 355 number of AEs | Number of Adverse Events = 302 number of AEs

Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus

Study: ACTRN12614000891628 (Pubmed | Nutr Metab Cardiovasc Dis). Phase: Phase 2. Enrollment: 36. Published: 2016-05-01.

CVR(cerebral vasodilator responsiveness) = 13.8 % | CVR(cerebral vasodilator responsiveness) = 8.9 %

Influence of Caloric Restriction and Resveratrol in the Sirtuin System in Women and Men Aged 55 to 65 Years.

Study: NCT01668836 (CTgov). Phase: Not Applicable. Enrollment: 48. Published: 2016-04-18.

Direct Evaluation of the Sirtuin 1 Gene Expression(Mean) = 11.04 arbitrary unit relative to control gene | Direct Evaluation of the Sirtuin 1 Gene Expression(Mean) = 11.43 arbitrary unit relative to control gene

Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors

Study: NCT02062190 (Pubmed | Nutrients). Phase: Phase 2. Enrollment: 19. Published: 2016-01-29.

BFM: P-Value = 0.038 | BFM: P-Value = 0.038

Anti-Inflammatory Effects of Resveratrol in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study

Study: IRCT201209154010N10 (Pubmed | Arch Med Res). Phase: Not Applicable. Enrollment: 50. Published: 2015-05-01.

TNF-α = 17.2 pg/mL

Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

Study: NCT02114892 (CTgov). Phase: Phase 2. Enrollment: 24. Published: 2014-12-29.

Triglycerides Levels at Week 12(Mean) = 210.6 mg/dL | Triglycerides Levels at Week 12(Mean) = 235.8 mg/dL

A novel red grape cells complex: health effects and bioavailability of natural resveratrol

Study: NCT01747252 (Pubmed | Int J Food Sci Nutr). Phase: Not Applicable. Enrollment: 15. Published: 2014-11-01.

LDL oxidation = 8.0 μg/mL

Effect of resveratrol on exercise capacity: a randomized placebo-controlled crossover pilot study

Study: NCT01615445 (Pubmed | Appl Physiol Nutr Metab). Phase: Phase 2. Enrollment: 13. Published: 2014-10-01.

FBG = small reduction | FBG = small reduction

Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects

Study: NCT00998504 (Pubmed | Diabet Med). Phase: Not Applicable. Enrollment: 10. Published: 2013-10-01.

Postprandial glucagon = 4.4 min × nmol/l | Postprandial glucagon = 3.9 min × nmol/l

Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance

Study: Pubmed | J Gerontol A Biol Sci Med Sci. Phase: Phase 2. Enrollment: 10. Published: 2012-12-01.

Peak postmeal glucose = 166 mg/dL

Resveratrol enhances Glut-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium

Study: Pubmed | J Cell Mol Med. Phase: Phase 2. Enrollment: 24. Published: 2008-12-01.

Blood glucose level = 587 mg/dL | Blood glucose level = 375 mg/dL

High absorption but very low bioavailability of oral resveratrol in humans

Study: NCT02114892 (Pubmed | Drug Metab Dispos). Phase: Phase 2. Enrollment: 6. Published: 2004-12-01.

Absorption = 70 %

For every reported endpoint, obtain the protocol, statistical analysis plan, patient disposition, baseline characteristics, subgroup definitions, exposure duration, and full safety tables. Conference abstracts and registry summaries can support screening, but they should not replace source data review in a binding transaction.

Use PatSnap Life Sciences MCP servers to validate the Resveratrol diligence evidence.

4. Market and competitive position

The commercial case depends on differentiated efficacy, tolerability, convenience, biomarker reach, treatment setting, and access. A target-level market may be attractive while an individual asset remains undifferentiated. Benchmark Resveratrol against approved therapies and clinical competitors in Parkinson Disease, including likely standards of care at the expected launch date.

Build a scenario model around addressable patients, diagnosis and biomarker rates, line of therapy, duration, net price, uptake, displacement, combination costs, and probability-adjusted timelines. Test slower enrollment, delayed readout, narrower labels, safety restrictions, and competitor launches.

Use PatSnap Life Sciences MCP servers to validate the Resveratrol diligence evidence.

5. Transaction precedent and economics

Transaction records should be normalized for territory, asset scope, phase at signing, option mechanics, development obligations, cost sharing, royalties, milestones, and change-of-control terms. Undisclosed economics must not be converted into invented benchmarks.

6. IP and freedom-to-operate screen

Complete a family-level patent review covering composition of matter, sequence or construct claims, polymorph and salt claims, formulation, dosing, combinations, biomarkers, manufacturing, and method of use. Verify priority, ownership, assignments, prosecution status, term adjustments, extensions, oppositions, and regional coverage. Freedom to operate is a separate legal analysis and should include competitor claims and platform dependencies.

The diligence room should reconcile inventorship, employee and contractor assignments, university or platform licenses, sublicensing restrictions, government rights, and obligations triggered by development milestones or commercialization.

Use PatSnap Life Sciences MCP servers to validate the Resveratrol diligence evidence.

7. Principal risks and diligence gates

1. Identity risk: resolve all aliases, formulations, combinations, and owners.
2. Clinical risk: confirm source data, protocol deviations, endpoint definitions, and safety follow-up.
3. Regulatory risk: review agency correspondence, meeting minutes, holds, commitments, and indication-specific pathways.
4. IP risk: validate enforceable coverage, remaining life, ownership, and freedom to operate.
5. CMC risk: assess process control, analytical methods, comparability, scale-up, supply, and cost of goods.
6. Commercial risk: pressure-test differentiation, market access, competitive timing, and realistic adoption.
7. Transaction risk: map rights, encumbrances, royalties, options, consent requirements, and change-of-control provisions.

8. Final go/no-go memorandum

CONDITIONAL GO

Proceed only through staged diligence. Before exclusivity or a binding offer, require a verified asset identity package, complete clinical data room, regulatory correspondence, patent-family schedule, freedom-to-operate opinion, CMC package, ownership chain, regional rights map, and risk-adjusted valuation. Any material mismatch between public records and source documents should pause the process until reconciled.

Method note: This report uses PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP data retrieved on 2026-10-14. It is a screening and diligence framework, not medical, legal, regulatory, or investment advice.